Cannabidiol reduces alcohol craving: ICONIC trial (RCT)

Introduction and clinical context

The study Cannabidiol reduces alcohol craving: ICONIC trial (RCT) (PubMed · 2024) is part of the scientific research on the use of cannabinoids in alcohol and tobacco.

Cannabidiol (CBD) is investigated in the field of addictions as a possible aid in reducing craving for alcohol and cigarette consumption. Clinical trials and pilot studies suggest an effect on the craving and the consumption behavior in some participants, with hypotheses linked to the modulation of reward circuits. The research is early and the content is informative, aimed at harm reduction and treatment — not at encouraging consumption.

Understanding what science shows about the use of cannabinoids in alcohol and tobacco helps patients and healthcare professionals make safer, well-founded decisions, based on evidence rather than common sense.

Methodology and findings

This clinical trial was conducted in a controlled manner, comparing the treatment with a reference group. Double-blind RCT: a single dose of CBD 800 mg reduced alcohol craving and nucleus accumbens activation. The blinded, controlled design reduces bias and increases the reliability of the finding. Results from controlled trials like this are especially valuable for guiding therapeutic decisions.

Mechanism of action and safety

In the field of addictions, CBD is investigated for modulating reward circuits and cue-reactivity linked to craving, possibly reducing the desire to consume alcohol and tobacco. It is generally well tolerated, but can cause drowsiness, fatigue and appetite changes, with attention to drug interactions. The research is preliminary and aimed at harm reduction. Managing addictions is multidisciplinary, and the cannabinoid is studied as a possible aid — not as a substitute for treatment.

Regulation in Brazil (Anvisa)

In Brazil, access to cannabis products is regulated by Anvisa — mainly through RDC 660/2022 (patient import with a medical prescription) and the new manufacturing and import framework, RDC 1,015/2026. Any therapeutic use must start from an individualized medical assessment and prescription. This content is informative and scientific and does not replace the guidance of a healthcare professional.

This is informative content produced by Brazcann; for the full methodology and detailed results, consult the original publication (PubMed · 2024). Access to cannabis treatments must always occur through the regulated pathway, with a prescription and medical follow-up.

Frequently asked questions

Does CBD help to quit smoking or drinking?

Early studies suggest a reduction in craving and consumption in some participants; the evidence is preliminary.

Does this content encourage consumption?

No. The focus is the treatment and harm reduction of addictions.